Head‐to‐head comparison of palbociclib and ribociclib in first‐line treatment of HR‐positive/HER2‐negative metastatic breast cancer with real‐world data from the OPAL registry DOI Creative Commons
Marc Thill, Mark‐Oliver Zahn, Anja Welt

и другие.

International Journal of Cancer, Год журнала: 2024, Номер unknown

Опубликована: Дек. 20, 2024

Abstract Cyclin‐dependent kinase 4/6 inhibitors (CDKIs) in combination with endocrine therapy (ET) are the standard‐of‐care first‐line treatment of HR‐positive, HER2‐negative metastatic breast cancer. In absence direct head‐to‐head trials comparing efficacy and safety different CDKIs, individual choice everyday practice is complex. Inverse probability weighting was used to emulate a comparison palbociclib +ET (PALBO) ribociclib (RIBO) patients recruited into prospective, observational, multicenter registry platform OPAL (NCT03417115). Progression‐free survival (PFS), overall (OS) quality life surveys were analyzed, also for subgroups stratified by treatment‐free interval (TFI). A total 623 cancer received PALBO ( n = 388) or RIBO 235) their first line treatment. No difference between found PFS (median 26.7 months [23.6, 30.7] vs. 27.0 [21.1, 30.4], HR 1.01 [0.80, 1.27]) OS 42.4 [38.8, 50.3] 49.3 [36.9, NA], 0.96 [0.71, 1.28]). There trend longer TFI <12 receiving RIBO. Patients reported comparable side effects both CDKIs. This revealed no RIBO, however, observed subgroup months. Side experienced highlight important toxicities be addressed during decision.

Язык: Английский

HER2-Positive Breast Cancer Treatment and Resistance DOI
Jamunarani Veeraraghavan, Carmine De Angelis, Carolina Gutiérrez

и другие.

Advances in experimental medicine and biology, Год журнала: 2025, Номер unknown, С. 495 - 525

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

2
Seize the engine: Emerging cell cycle targets in breast cancer DOI Creative Commons
Jesús Fuentes‐Antrás, Philippe L. Bédard, David W. Cescon

и другие.

Clinical and Translational Medicine, Год журнала: 2024, Номер 14(1)

Опубликована: Янв. 1, 2024

Язык: Английский

Процитировано

12
PROTAC: Novel degradable approach for different targets to treat breast cancer DOI Creative Commons
Zhenjie Wang, Siyao Che,

Zhiqiang Yu

и другие.

European Journal of Pharmaceutical Sciences, Год журнала: 2024, Номер 198, С. 106793 - 106793

Опубликована: Май 11, 2024

The revolutionary Proteolysis Targeting Chimera (PROTACs) have the exciting potential to reshape pharmaceutical industry landscape by leveraging ubiquitin-proteasome system for targeted protein degradation. Breast cancer, most prevalent cancer in women, could be treated using PROTAC therapy. Although substantial work has been conducted, there isn't yet a comprehensive overview or progress update on therapy breast cancer. Hence, this article, we've compiled recent research focusing different target proteins, such as estrogen receptor (ER), BET, CDK, HER2, PARP, EZH2, etc. This resource aims serve guide future PROTAC-based treatment design.

Язык: Английский

Процитировано

5
Cyclin‐dependent kinase 5 (CDK5) inhibitors in Parkinson disease DOI Creative Commons
Mohammed Alrouji,

Haydar M. Al‐kuraishy,

Ali I. Al‐Gareeb

и другие.

Journal of Cellular and Molecular Medicine, Год журнала: 2024, Номер 28(11)

Опубликована: Июнь 1, 2024

Abstract Cyclin‐dependent kinase 5 (Cdk5) is a protein expressed in postmitotic neurons the central nervous system (CNS). Cdk5 activated by p35 and p39 which are neuron regulatory subunits. Cdk5/p35 complex calpain protease to form has neuroprotective effect regulating synaptic plasticity memory functions. However, exaggerated implicated different types of neurodegenerative diseases including Parkinson disease (PD). Therefore, modulation signalling may mitigate PD neuropathology. aim present review was discuss critical role pathogenesis PD, how inhibitors effectual management PD. In conclusion, overactivated involved development neurodegeneration, Cdk5/calpain such as statins, metformin, fenofibrates rosiglitazone can attenuate progression

Язык: Английский

Процитировано

5
Advances in Ultrasound-Targeted Microbubble Destruction (UTMD) for Breast Cancer Therapy DOI Creative Commons

Yunfeng Wu,

Yu-xi Liu, Han Wu

и другие.

International Journal of Nanomedicine, Год журнала: 2025, Номер Volume 20, С. 1425 - 1442

Опубликована: Фев. 1, 2025

Abstract: Breast cancer is one of the most common types in women worldwide and a leading cause deaths among women. As result, various treatments have been developed to combat this disease. treatment varies based on its stage type pathology. Among therapeutic options, ultrasound has employed assist breast cancer, including radiation therapy, chemotherapy, targeted immunotherapy, hormonal and, more recently, radiofrequency ablation for early-stage inoperable patients. One notable advancement ultrasound-targeted microbubble destruction (UTMD), which gradually becoming highly effective non-invasive anti-tumor modality. This technique can enhance chemical, genetic, immune, anti-vascular therapies through physical biological effects. Specifically, UTMD improves drug transfer efficiency destroys tumor neovascularization while reducing toxic side effects body during treatment. Given these developments, application ultrasound-assisted therapy gained significant attention from research scholars. In review, we will discuss development modalities importantly, highlight microbubble-targeted disruption techniques Keywords: destruction, microbubble, TME,

Язык: Английский

Процитировано

0
Exploring the Potential of Adjuvant CDK4/6 Inhibitors in Hormone Receptor-Positive Early Breast Cancer: A Consistent Approach for All DOI Open Access

Jianbin Li

Cancers, Год журнала: 2025, Номер 17(4), С. 561 - 561

Опубликована: Фев. 7, 2025

Hormone receptor-positive, HER2-negative breast cancer is the most common subtype, with endocrine therapy as standard treatment. Despite advancements in adjuvant therapy, recurrence remains a challenge, particularly high-risk patients. Recent trials on cyclin D kinase 4/6 (CDK4/6) inhibitors have shown promise reducing early and improving survival. This review analyzes clinical evidence supporting use of CDK4/6 inhibitors, focusing NATALEE monarchE trials, which demonstrate comparable efficacy manageable safety profiles for ribociclib abemaciclib. Ribociclib, its broader applicability impact decision making axillary lymph node surgery, may be preferred option populations. The also addresses unanswered questions highlights need ongoing research to optimize strategies.

Язык: Английский

Процитировано

0
Capecitabine with aromatase inhibitors in the front-line therapy for metastatic breast cancer DOI Creative Commons

Masakazu Toi

Breast Cancer, Год журнала: 2025, Номер unknown

Опубликована: Март 27, 2025

Язык: Английский

Процитировано

0
A real-world drug safety surveillance study from the FAERS database of breast cancer patients receiving abemaciclib alone and plus letrozole DOI
Lu Hu,

Yong Ran,

Chunqiao Zhou

и другие.

Research Square (Research Square), Год журнала: 2025, Номер unknown

Опубликована: Апрель 16, 2025

Abstract Abemaciclib in combination with letrozole is considered a crucial treatment regimen for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) breast cancer. This study aims to monitor and identify adverse events (AEs) associated this therapy enhance patient safety provide evidence-based recommendations the appropriate use of these drugs. We collected data on drug reactions (ADRs) related cancer patients receiving either abemaciclib monotherapy or its from FDA Adverse Event Reporting System (FAERS) database between first quarter 2014 fourth 2024. ADR signal detection was conducted using reporting odds ratio (ROR), proportional (PRR), Bayesian confidence propagation neural network (BCPNN), multi-item gamma Poisson shrinker (MGPS) methods. A total 6,649 750 AE cases were letrozole, respectively. Using four techniques, we identified 42 28 distinct AEs, involving 15 11 different system organ class (SOC) categories, The most common AEs diarrhea, dehydration, myelosuppression. In group, frequently reported interstitial lung disease, acute kidney injury (AKI). Additionally, observed higher incidence abnormal liver function detected hepatocellular necrosis. United States highest number followed by Japan, China, France, Italy. median onset time 30 days (interquartile range [IQR]: 11–115 days) 35 (IQR: 14–109 days), provides novel insights into monitoring management ADRs letrozole.

Язык: Английский

Процитировано

0
Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases DOI Creative Commons
Robert Roskoski

Pharmacological Research, Год журнала: 2023, Номер 199, С. 107036 - 107036

Опубликована: Дек. 12, 2023

Because genetic alterations including mutations, overexpression, translocations, and dysregulation of protein kinases are involved in the pathogenesis many illnesses, this enzyme family is target drug discovery programs worldwide. The FDA has approved 80 small molecule kinase inhibitors with 77 drugs orally bioavailable. data indicate that 69 these medicinals for management neoplasms solid tumors such as breast lung cancer well non-solid leukemia. Moreover, remaining 11 non-neoplastic diseases psoriasis, rheumatoid arthritis, ulcerative colitis. cost was obtained from www.pharmacychecker.com using label to determine dosage number tablets required per day. This methodology excludes any private or governmental insurance coverage, which would cover entire more likely a fraction stated price. average monthly treatment neoplastic $17,900 price $44,000 futibatinib (used treat cholangiocarcinomas FGFR2 fusions) minimum $5100 binimetinib (melanoma). $6800 maximum $17,000 belumosudil (graft vs. host disease) $200 netarsudil eye drops (glaucoma). There negative correlation incidence targeted disease. Many agents were designated orphan meaning there fewer than 200,000 potential patients United States.

Язык: Английский

Процитировано

9
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib DOI Creative Commons
Vincent D. de Jager,

Jos A. Stigt,

Maarten Niemantsverdriet

и другие.

npj Precision Oncology, Год журнала: 2024, Номер 8(1)

Опубликована: Май 22, 2024

Abstract Precision cancer medicine has changed the treatment paradigm of patients with non-small cell lung (NSCLC) specific molecular aberrations. A major challenge is management resistance that tumor cells eventually develop against targeted therapies, either through primary or acquired mechanisms. We report a 61 year-old male patient metastatic NSCLC harboring an EGFR exon 19 deletion, PIK3CA mutation, and CDK4 amplification. After initial partial response to osimertinib as mono-therapy (third-generation tyrosine kinase inhibitor), had progression disease after 4 months was referred for combined palbociclib (CDK4/6 inhibitor) treatment. Though complicated by transient pneumonitis, ongoing > 10 experienced clinical improvement on this regimen. As amplification occurs in ~ 10% treatment-naïve EGFR-mutated NSCLC, successful our may be highly relevant future NSCLC.

Язык: Английский

Процитировано

3